Search clinical trials for: ellaOne® (ulipristal acetate)

Total 309 results

University of Campinas, Brazil

Unknown

Ulipristal Versus Placebo for Women With Bleeding Induced by Mirena

Heavy Menstrual Bleeding | Abnormal Bleeding

Brazil
Population Council

Unknown

A Study to Evaluate the Effect of a Contraceptive Vaginal Ring Delivering Ulipristal Acetate Combined With a Single or Repeated Levonorgestrel on Inhibition of Ovulation, Endometrial Changes and Bleeding Patterns in Normal Cycling Women

Ovulation Inhibition

Dominican Republic
HRA Pharma

Completed

Safety and Efficacy of CDB-2914 for Emergency Contraception

Emergency Contraception

United States
Repros Therapeutics Inc.

Terminated

An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

Uterine Fibroids

United States
Eunice Kennedy Shriver National Institute of Child...

Completed

Use of the Synthetic Hormone CDB-2914 in Treating Symptoms of Menopause

Postmenopause

United States
Eli Lilly and Company

Completed

A Study to Measure the Amount of Evacetrapib That Enters the Blood Stream in Healthy Participants

Healthy Volunteers

United Kingdom
Repros Therapeutics Inc.

Completed

Safety and Efficacy of Telapristone Acetate (Proellex®) in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic Endometriosis

Endometriosis

United States
Repros Therapeutics Inc.

Completed

Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids

Uterine Fibroids

United States
Population Council

Completed

Study to Evaluate the Safety and Efficacy of Two Contraceptive Vaginal Rings Delivering a Daily Dose of 1500 or 2500 μg of CDB-2914

Contraception

United States, Dominican Republic, Chile
Repros Therapeutics Inc.

Completed

A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

Uterine Fibroids

United States
Oregon Health and Science University
Society of Family Planning

Completed

Impact of Combined Hormonal Contraceptives on UPA

Contraception

United States
Stanford University

Completed

On Demand Contraception: Ulipristal Acetate Plus a COX-2 Inhibitor at Peak Fertility

Contraception

United States
Eunice Kennedy Shriver National Institute of Child...

Completed

Comparison of Blood Levels of Two Formulations of the Selective Hormone Receptor Modulator CDB-2914

Healthy

United States
Eli Lilly and Company

Completed

A Study to Evaluate the Effect of Increased Stomach pH on Evacetrapib in Healthy Participants

Healthy

United States
Repros Therapeutics Inc.

Completed

Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003

Uterine Fibroids

United States
Oregon Health and Science University
National Institutes of Health (NIH)

Completed

Effectiveness of Orally Dosed Emergency Contraception in Obese Women - UPA (UPA-Obesity)

Obesity | Contraception

United States
Planned Parenthood of the St. Louis Region and...
University of Colorado, Denver; University of Rochester; Planned Parenthood Federation... and other collaborators

Completed

Levonorgestrel Intrauterine System For Emergency Contraception (LIFE)

Pregnancy, Unplanned | Pregnancy; Accident

United States
PregLem SA

Completed

PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata (PEARLIII)

Uterine Fibroids

Belgium, Poland, Austria, Spain
AstraZeneca

Withdrawn

To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer. (LARES)

Breast Cancer

China
Ontario Clinical Oncology Group (OCOG)
AstraZeneca

Completed

Immediate Versus Deferred Androgen Deprivation Therapy,Goserelin for Recurrent Prostate Cancer After Radical Radiotherapy (ELAAT)

Prostate Cancer

Canada
Bial - Portela C S.A.

Completed

Bioequivalence of Two Different Sources of Eslicarbazepine Acetate

Epilepsy
PregLem SA

Completed

PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata (PEARLIII-extension Study)

Uterine Fibroids

Poland, Spain, Austria, Belgium
Synthon BV

Completed

Efficacy and Safety of GTR in Comparison to Copaxone® (GATE)

Multiple Sclerosis

United States, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Georgia, Germany, Italy, Mexico, Moldova, Republic of, Poland, Romania, Russian Federation, Serbia, South Africa, Ukraine, United Kingdom
Azidus Brasil

Suspended

Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg Compared To Product Sandostatin LAR ®

Acromegaly

Brazil
Eurofarma Laboratorios S.A.

Recruiting

Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients With Breast Cancer

Breast Cancer

India
Merckle GmbH

Completed

Study to Compare the Bioavailability, Safety and Tolerability of XM17 in Healthy, Down Regulated Young Women

Bioequivalence
Rigshospitalet, Denmark
Octapharma

Terminated

Vasculopathic Injury and Plasma as Endothelial Rescue in Septic Shock Trial. VIPER-Sepsis (EudraCT no. 2016-000707-81)

Septic Shock

Denmark
Diskapi Teaching and Research Hospital

Not yet recruiting

Carotid Flow Time Measurement Guided Fluid Management During Spinal Anesthesia

Meniscus Disorder

Turkey
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome (PreCISe)

Multiple Sclerosis
AstraZeneca

Completed

Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women

Advanced Breast Cancer

Russian Federation, Ukraine, Czech Republic
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).

Relapsing Remitting Multiple Sclerosis
PregLem SA

Completed

PGL4001 Versus GnRH-agonist in Uterine Myomas (PEARLII)

Uterine Myomas

Spain, Germany, Austria, Israel, Poland, Italy, Belgium, France, Netherlands
Neurognostics

Terminated

An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis

Relapsing-Remitting Multiple Sclerosis

United States
Sheba Medical Center

Unknown

An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetate on Girls Woth Rett Syndrome

Rett Syndrome

Israel
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness

Relapsing-Remitting Multiple Sclerosis

United States
Luye Pharma Group Ltd.

Completed

Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®

Prostate Cancer

China
Teva Neuroscience, Inc.

Completed

Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients (ENCORE)

Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.

Multiple Sclerosis
Bial - Portela C S.A.

Completed

Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive

Partial Epilepsy

Portugal
Vifor Fresenius Medical Care Renal Pharma

Terminated

A Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With Hyperphosphataemia

Hyperphosphatemia

United States, Poland, Germany, Lithuania, France, Romania, Russian Federation
Genzyme, a Sanofi Company

Completed

Study of Safety and Efficacy of Renagel® Compared With Calcium Acetate in Patients With Peritoneal Dialysis

Peritoneal Dialysis | Chronic Kidney Disease

Belgium, United Kingdom, Denmark, France, Italy, Netherlands, Spain
Luye Pharma Group Ltd.

Completed

Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®

Prostate Cancer

China
AstraZeneca

Completed

Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD Patients (MAESTRO)

GERD

France
Yuria-Pharm

Completed

Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Sepsis.

Sepsis | Intoxication; Septic

Georgia, Moldova, Republic of, Ukraine, Uzbekistan, Kazakhstan
Yuria-Pharm

Completed

Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Pneumonia

Pneumonia

Georgia, Moldova, Republic of, Kazakhstan, Ukraine, Uzbekistan, Vietnam
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline

Relapse Remitting Multiple Sclerosis
Sun Pharmaceutical Industries Limited

Completed

A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer (STAAR)

Prostate Cancer

United States
Yuria-Pharm

Completed

Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Peritonitis

Peritonitis | Intoxication

Georgia, Moldova, Republic of, Ukraine, Uzbekistan
Yuria-Pharm

Unknown

Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Burns

Burns | Intoxication

Kazakhstan, Moldova, Republic of, Ukraine, Uzbekistan
Merus N.V.

Recruiting

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Metastatic Castration-resistant Prostate Cancer | NSCLC Harboring NRG1 Fusion

United States

3

Subscribe